Cargando…
Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis
OBJECTIVE: In Japan, following the launch of dimethyl fumarate (DMF) after fingolimod as a disease-modifying drug in multiple sclerosis (MS), some patients switched from fingolimod to DMF. The aim of this study was to determine the follow-up status of MS patients who switched to DMF after fingolimod...
Autores principales: | Sato, Kazunori, Niino, Masaaki, Kawashima, Atsushi, Yamada, Moemi, Miyazaki, Yusei, Fukazawa, Toshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191590/ https://www.ncbi.nlm.nih.gov/pubmed/29709955 http://dx.doi.org/10.2169/internalmedicine.0793-18 |
Ejemplares similares
-
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels
por: Koda, Toru, et al.
Publicado: (2018) -
An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis
por: Niino, Masaaki, et al.
Publicado: (2002) -
Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022) -
Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study
por: Nakamura, Yuri, et al.
Publicado: (2016) -
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)